Pediatric Vouchers Could Limit Adult Rare Disease Development, US FDA Says
This article was originally published in SRA
The US Food and Drug Administration is continuing to lobby criticisms at the rare pediatric disease priority review voucher program even as it gains in popularity.
You may also be interested in...
Phase Ib data at ASH look competitive with new pivotal trial results for Bristol/bluebird’s leading BCMA CAR-T bb2121. The Phase II portion of the CARTITUDE-1 study for JNJ-4528 is fully enrolled.
Farah Ahmed, president and CEO of the Fragrance Creators Association, discusses the trade group’s expansion in recent years beyond immediate regulatory and legislative concerns to a platform for robust member collaboration in the name of positively impacting the world.